Knight Therapeutics Enters Exclusive Agreement with Kyowa Kirin International for Mogamulizumab

MT newswire2026/09/29 12:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

08:50 AM EDT, 09/29/2026 (MT Newswires) -- Knight Therapeutics (GUD.TO) has signed an agreement with Japan-based Kyowa Kirin International for the exclusive distribution of mogamulizumab, an antibody drug that treats lymphoma, across certain Latin American countries. Under the terms, Knight Therapeutics will be responsible for securing regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina, the company said Tuesday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Knight Therapeutics Enters Exclusive Agreement with Kyowa Kirin International for Mogamulizumab

You may also like

Crypto prices